Literature DB >> 24998838

Acute kidney injury defined according to the 'Risk,' 'Injury,' 'Failure,' 'Loss,' and 'End-stage' (RIFLE) criteria after repair for a ruptured abdominal aortic aneurysm.

Sytse C van Beek1, Dink A Legemate1, Anco Vahl2, Catherine S C Bouman3, Liffert Vogt4, Willem Wisselink5, Ron Balm6.   

Abstract

OBJECTIVE: Acute kidney injury (AKI) is a serious complication after repair of a ruptured abdominal aortic aneurysm (RAAA). In the present Society for Vascular Surgery (SVS)/International Society for CardioVascular Surgery (ISCVS) reporting standards patients are classified as no dialysis (grade I), as temporary dialysis (grade II), and as permanent dialysis or fatal outcome (grade III). However, AKI is a broad clinical syndrome including more than the requirement for renal replacement therapy. The recently introduced 'Risk,' 'Injury,' 'Failure,' 'Loss,' and 'End-stage' (RIFLE) classification for AKI comprises three severity categories based on serum creatinine and urine output ('Risk,' 'Injury,' and 'Failure'). The objective of the present study was to assess the incidence of AKI using the RIFLE criteria (AKIRIFLE). Secondary objectives were to assess the incidence of AKI as defined using the SVS/ISCVS reporting standards (AKISVS/ISCVS) and the association between AKIRIFLE and death.
METHODS: This was an observational cohort study in 362 consecutive patients with an RAAA in three hospitals in Amsterdam (The Netherlands) between 2004 and 2011. The end points were the incidence of AKIRIFLE, of AKISVS/ISCVS, and the combined 30-day or in-hospital death rate. A multivariable logistic regression model was made to assess the association between AKIRIFLE and death after adjustment for preoperative shock profile (Glasgow Aneurysm Score) and postoperative shock profile (Acute Physiology and Chronic Health Evaluation [APACHE] II score, use of vasopressors, and fluid balance during the first 24 hours after intervention).
RESULTS: AKIRIFLE occurred in 74% (267/362; 95% confidence interval [CI], 69%-78%), with 27% of these patients categorized as 'Risk' (71/267; 95% CI, 22%-32%), 39% categorized as 'Injury' (104/267, 95% CI, 33%-45%), and 34% categorized as 'Failure' (92/267; 95% CI, 29%-40%). AKISVS/ISCVS occurred in 48% (175/362; 95% CI, 43%-53%), with 53% of these categorized as 'grade I' (92/175; 95% CI, 45%-60%), 19% as 'grade II' (34/175; 95% CI, 14%-26%), and 28% as 'grade III' (49/175; 95% CI, 22%-35%). After multivariable adjustment for shock profiles the risk of dying in patients categorized as AKIRIFLE 'Failure' was greater than in patients without AKIRIFLE (adjusted odds ratio, 6.360; 95% CI, 2.231-18.130).
CONCLUSIONS: The incidence of AKI defined according to the RIFLE criteria (74%) was greater than defined using the SVS/ISCVS reporting standards (48%) and patients categorized as 'Failure' using the RIFLE criteria had a greater risk of dying than patients without AKI. These results indicate that the problem of AKI is much bigger than previously anticipated and that minimizing injury to the kidney could be an important focus of future research on reducing the death rate after RAAA repair.
Copyright © 2014 Society for Vascular Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24998838     DOI: 10.1016/j.jvs.2014.04.072

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  10 in total

1.  Nucleophosmin Phosphorylation as a Diagnostic and Therapeutic Target for Ischemic AKI.

Authors:  Zhiyong Wang; Erdjan Salih; Chinaemere Igwebuike; Ryan Mulhern; Ramon G Bonegio; Andrea Havasi; Steven C Borkan
Journal:  J Am Soc Nephrol       Date:  2019-01       Impact factor: 10.121

2.  Mortality and Cost of Acute and Chronic Kidney Disease after Vascular Surgery.

Authors:  Matthew Huber; Tezcan Ozrazgat-Baslanti; Paul Thottakkara; Philip A Efron; Robert Feezor; Charles Hobson; Azra Bihorac
Journal:  Ann Vasc Surg       Date:  2015-07-14       Impact factor: 1.466

Review 3.  Epidemiology, outcomes, and management of acute kidney injury in the vascular surgery patient.

Authors:  Charles Hobson; Nicholas Lysak; Matthew Huber; Salvatore Scali; Azra Bihorac
Journal:  J Vasc Surg       Date:  2018-06-28       Impact factor: 4.268

Review 4.  Perioperative Acute Kidney Injury: Risk Factors and Predictive Strategies.

Authors:  Charles Hobson; Rupam Ruchi; Azra Bihorac
Journal:  Crit Care Clin       Date:  2017-04       Impact factor: 3.598

Review 5.  Disease Mechanisms of Perioperative Organ Injury.

Authors:  Catharina Conrad; Holger K Eltzschig
Journal:  Anesth Analg       Date:  2020-12       Impact factor: 6.627

6.  Predictors of Acute Kidney Injury Following Elective Open and Endovascular Aortic Repair for Abdominal Aortic Aneurysm.

Authors:  Takao Nonaka; Naoyuki Kimura; Daijiro Hori; Yusuke Sasabuchi; Mitsunori Nakano; Koichi Yuri; Masamitsu Sanui; Harunobu Matsumoto; Atsushi Yamaguchi
Journal:  Ann Vasc Dis       Date:  2018-09-25

Review 7.  Postoperative Intensive Care Management of Aortic Repair.

Authors:  Stefano De Paulis; Gabriella Arlotta; Maria Calabrese; Filippo Corsi; Temistocle Taccheri; Maria Enrica Antoniucci; Lorenzo Martinelli; Francesca Bevilacqua; Giovanni Tinelli; Franco Cavaliere
Journal:  J Pers Med       Date:  2022-08-22

8.  The incidence, risk factors and in-hospital mortality of acute kidney injury in patients after abdominal aortic aneurysm repair surgery.

Authors:  Ying Tang; Junzhe Chen; Kai Huang; Dan Luo; Peifen Liang; Min Feng; Wenxin Chai; Erik Fung; Hui Yao Lan; Anping Xu
Journal:  BMC Nephrol       Date:  2017-05-31       Impact factor: 2.388

9.  Weekend effect in non-elective abdominal aortic aneurysm repair.

Authors:  G K Ambler; N B G Mariam; U Sadat; P A Coughlin; I M Loftus; J R Boyle
Journal:  BJS Open       Date:  2017-12-04

Review 10.  Acute Renal Failure/Acute Kidney Injury (AKI) Associated with Endovascular Procedures.

Authors:  Zbigniew Krasinski; Beata Krasińska; Marta Olszewska; Krzysztof Pawlaczyk
Journal:  Diagnostics (Basel)       Date:  2020-05-02
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.